Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic®P85, an in vitro cell line and in vivo biodistribution studies on rat model

Journal of Drug Targeting

Volumn 17, Issue 7, 2009, Pages 533-542

  Shah, Neha ^a   Chaudhari, Kiran ^a   Dantuluri, Prudhviraju ^a   Murthy, R S R ^a   Das, Susobhan ^b  

^a New Drug Delivery Systems   (India)

^b Intas Biopharmaceuticals Ltd   (India)

Author keywords

C6 glioma; Multidrug resistance; Paclitaxel; Pluronic P85; Transferrin anchored PLGA NPs

Indexed keywords

GLYCOPROTEIN P; NANOPARTICLE; PACLITAXEL; PLURONIC P85; POLOXAMER; POLYGLACTIN; TRANSFERRIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER; LACTIC ACID; PLURONIC BLOCK COPOLYMER P85; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SYNTHESIS; GLIOMA; GLIOMA CELL; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR CELL LINE; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DRUG RESISTANCE; DRUG SCREENING; METABOLISM; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG CARRIERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOMA; LACTIC ACID; MALE; NANOPARTICLES; P-GLYCOPROTEINS; PACLITAXEL; POLOXALENE; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; TRANSFERRIN;

EID: 70349785875     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860903046628     Document Type: Article

References (22)

1. Ambudkar S, Lelong I, Zhang J, Cardarelli C, Gottesman M, Pastan I. (1992). Partial purification and reconstitution of the human multidrug resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci USA, 89, 8472-8476.
2. Chen DB, Yang TZ, Lu WL, Zhang Q. (2001). In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing Paclitaxel. Chem Pharm Bull, 49(11), 1444-1447.
3. Desai MP, Labhasetwar V, Walter E, Levy RJ. (1997). The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res, 14, 1568-1573.
4. Endicott J, Ling V. (1989). The biochemistry of P glycoprotein mediated multidrug resistance. Annu Rev Biochem, 58, 137-171.
5. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. (1989). Nanocapsule formation by interfacial deposition following solvent displacement. Int J Pharm, 55, R1-R4.
6. Fonseca C, Simoes S, Gaspar R. (2002). Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release, 83, 273-286.
7. Kabanov AV, Batrakova EV, Alakhov V. (2002a). Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev, 54, 759-779.
8. Kabanov AV, Batrakova EV, Alakhov V. (2002b). Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release, 82, 189-212. (Pubitemid 34880178)
9. Konan YN, Gurny R, Konan YN, Gurny R. (2002). Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm, 233, 239-252.
10. Magenheim B, Levy MY, Benita S. (1993). A new in vitro technique for evaluation of drug release profile from colloidal carriers-ultrafiltration technique at low pressure. Int J Pharm, 94, 115-123.
11. Moghimi SM, Muir IS, Illum L, Davis SS, Kolb-bachofen V. (1993). Coating particles with block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta, 1179, 157-165.
12. Mu L, Feng SS. (2003). PLGA/TPGS nanoparticles for controlled release of paclitaxel: effects of the emulsifier and the drug loading ratio. Pharm Res, 20(11), 1864-1872.
13. Muller RH, Wallis KH. (1993). Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int J Pharm, 89, 25-31.
14. Owens J. (2001). Stealthy polymers target drug-resistant tumour cells. Drug Discov Today, 6, 551-552.
15. Qian ZM, Li H, Sun H, Ho K. (2002). Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev, 54, 561-587.
16. Sahoo SK, Labhasetwar V. (2005). Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm, 2, 373-383.
17. Sahoo SK, Wenxue MA, Labhasetwar V. (2004) Efficacy of transferrinconjugated paclitaxel-loaded Nanoparticles in a murine model of prostate cancer. Int. J. Cancer 112, 335-340.
18. Schinkel A. (1999). P Glycoprotein, a gatekeeper in the blood brain barrier. Annu Rev Neurosci, 22, 11-28.
19. Sharma A, Sharma S, Khuller GK.(2004). Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J of Antimicrobial Chemotherapy 54, 761-766.
20. Spencer CM, Faulds D. (1994). Paclitaxel-a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs, 48, 794-847. (Pubitemid 24304427)
21. Stella B, Arpicco S, Peracchia MT, Desmaele D, Hoebeke H, Renoir M, D'Angelo J, Cattel L, Couvreur P. (2000). Design of folic-acidconjugated nanoparticles for drug delivery. J of Pharm Sci 89 (11), 1452-1464.
22. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. (1971). Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc, 93, 2325-2327.